Lydia Warburton

Hospital Avenue
Nedlands, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 06, 2026

Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).

Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 25, 2026

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 29, 2025

The Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer.

The Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer.

Journal: Cancer medicine

Published: August 11, 2025

Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA).

Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA).

Journal: JTO clinical and research reports

Published: June 06, 2025

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 01, 2025

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 30, 2025

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 26, 2024

A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

A scoping review of factors influencing the implementation of liquid biopsy for cancer care.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 21, 2024

Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.

Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 11, 2024

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).

Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).

Journal: Clinical lung cancer

Published: December 13, 2023

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.

Journal: Frontiers in oncology

Published: October 02, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026